ND

Nathan Davis

Analyst at RA Capital Management

Greater Boston

Overview 

Nathan Davis is currently an Analyst at RA Capital Management, LLC in Greater Boston, with a background in immunofluorescent Western Blot analysis and Fluorescent Confocal Microscopy. He has held various board observer roles in biotech companies and has expertise in statistical analysis, financial modeling, and operations management. Notable highlights of Nathan's career include serving as Executive Chair for the Covid Apollo Project and being involved in early-stage startups and mergers & acquisitions within the biotech and fintech sectors.

Work Experience 

S

StudioDx

  • Co-Founder

    2024 - Current

RC

RA Capital Management

  • Consultant

    2024

  • Analyst

    2022 - 2024

    Nate Davis is an Analyst on the Investment Team at RA Capital Management. Nate conducts due diligence on biotechnology companies at RA Capital and serves as a Board Director for The Covid Apollo Project and Nucleix. Previously, Nate worked closely with the Investment Team, as a Senior Associate within the TechAtlas division, to originate conviction in potential investments by identifying breakthroughs and putting data into context. Prior to RA Capital, Nate worked as an Investment Analyst at Wolfram Ventures. Nate has a BS in Biological Sciences from University of Vermont.

  • Associate

    2019 - 2022

    I am an Associate with the TechAtlas division of RA Capital Management. My primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities.

RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.

racap.com
NI

NanoMosaic Inc.

  • Board Observer

    2021 - 2024

NanoMosaic provides solutions for early illness detection, prognostic monitoring, and biomarker identification.

Raised $40,750,000.00 from TigerGene, Insight Partners, TIME BioVentures, RA Capital Management and Pura Vida Investments.

nanomosaicllc.com
AB

Ansa Biotechnologies, Inc.

  • Board Observer

    2021 - 2024

Ansa Biotechnologies develops a novel DNA synthesis technology based on enzymes.

Raised $83,419,682.00 from Humboldt Fund, RA Capital Management, Fifty Years, Peak 6, Altitude Life Science Ventures, Fiscus Ventures, Northpond Ventures, Horizons Ventures, Mubadala Capital Ventures and Carbon Silicon Ventures.

ansabio.com
NL

Nucleix Ltd.

  • Board Member

    2021 - 2024

CA

Covid Apollo Project

  • Executive Chair

    2021 - 2023

3EO Health

  • Board Observer

    2021 - 2022

AT

Acrivon Therapeutics, Inc.

  • Board Observer

    2021 - 2022

Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.

Raised $245,500,000.00 from RA Capital Management, Surveyor Capital, Perceptive Advisors, Acorn Bioventures, Paradigm BioCapital Advisors and Sands Capital Ventures.

acrivon.com

DICE Therapeutics

  • Board Observer

    2021 - 2021

M

MassBio

  • MassConnect Mentor

    2018 - 2019

Education 

Articles About Nathan

Relevant Websites